<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>KARDIOTONIKLAR VA ANTIANGINAL VOSITALAR YURAK-QON  TOMIR TIZIMI KASALLIKLARINI DAVOLASHDA MUHIM O‘RIN  TUTUVCHI FARMAKOLOGIK PREPARATLAR HISOBLANADI</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Kibriyeva</mods:namePart><mods:namePart type="family">Maxfirat</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Abduvohidova</mods:namePart><mods:namePart type="family">Madina</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Kardiotonik vositalar yurak mushagining qisqarish kuchini oshirib, yurak yetishmovchiligi holatlarida gemodinamik ko‘rsatkichlarni yaxshilaydi. Antianginal preparatlar esa miokardning kislorodga bo‘lgan ehtiyojini kamaytirish yoki toj tomirlar orqali qon oqimini yaxshilash orqali stenokardiya xurujlarini kamaytirishga xizmat qiladi. Ushbu maqolada kardiotonik va antianginal vositalarning farmakodinamikasi, farmakokinetikasi, asosiy ta’sir mexanizmlari, klinik qo‘llanilishi va nojo‘ya ta’sirlari ilmiy adabiyotlar asosida tahlil qilindi. Tadqiqot natijalari ushbu preparatlarning yurak yetishmovchiligi va ishemik yurak kasalliklarini davolashdagi samaradorligini tasdiqlaydi hamda zamonaviy farmakoterapiyada ularning o‘rnini yoritadi.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2026-06-06</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Research Science and Innovation House</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>